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For detection of respiratory syncytial virus (RSV), the BD Directigen RSV rapid antigen assay was compared
to Cepheid’s real-time reverse transcriptase PCR RSV analyte-specific reagents. The Directigen RSV assay
resulted in a 23% false-negative rate, using PCR and chart review as the gold standard, indicating that rapid
RSV PCR results would be advantageous.
Rapid detection of respiratory viruses is important for many
reasons, including prevention of unnecessary antibiotic use,
identification of individuals who can benefit from antivirals,
and improvement of infection control by grouping individuals
with the same viral infection. Respiratory syncytial virus (RSV)
is the most common cause of bronchiolitis in young children
(17). Three percent of all children are hospitalized with bron-
chiolitis in the first year of life, and RSV is the most common
cause of this hospitalization (2). An estimated 50% of all chil-
dren are infected with RSV during the first year of life, and by
3 years of age, 100% have experienced at least one infection
(14). Since RSV infection does not induce protective immu-
nity, reinfection is common.
Diagnosis of RSV infection can be made by observation of
clinical signs and symptoms, characteristic chest radiographs,
rapid antigen detection, viral culture, or reverse transcriptase
PCR (RT-PCR) of nasopharyngeal (NP) specimens (2). The
most common laboratory method for rapid detection of RSV
includes rapid antigen (enzyme immunoassay) assays produced
by multiple manufacturers, with various sensitivities of 57 to
98% and specificities between 70 and 100% (1, 5, 10, 11, 13, 16,
20). Other diagnostic tests include culture (routine tissue cul-
ture and shell vial culture), with sensitivities between 70 and
80% and specificities of 100% (10, 11, 19), and direct fluores-
cent antigen detection, with sensitivities between 93 and 100%
and specificities of 95 to 100% (1, 10, 16). More recently,
real-time RT-PCR assays have been described as demonstrat-
ing sensitivities of 73 to 97% and specificities of 64 to 99% (7,
9, 11). In this study, we compared assays using Cepheid’s RSV
analyte-specific reagents (ASR) to the BD Directigen RSV
rapid antigen assay (BD Diagnostics, Sparks, MD).
Respiratory specimens (n  142) consisting of NP aspirates
(n  140) and NP swabs (n  2) from the 2005-2006 peak
season were initially tested for RSV by the rapid antigen assay,
following the manufacturer’s protocol. The samples were put
into 2 ml of viral transport media prior to being tested; for NP
aspirates, the entire volume received was inoculated. These
specimens were from patients ranging from 3 days to 74 years
of age. Sixty-eight percent (n  96) of the specimens were from
infants (less than 1 year of age), 21% (n  30) from individuals
between 1 and 5 years of age, and 11% (n  16) from individ-
uals who were greater than 5 years of age. By the rapid antigen
assay, 34% (n  48) of the specimens were RSV positive. Of
the positives, 81% (n  39) were from individuals less than 1
year of age, 13% (n  6) from individuals 1 to 5 years of age,
and 6% (n  3) from individuals greater than 5 years of age.
Retrospectively, the same specimens were tested using the
Cepheid RSV ASR, which detect the nucleocapsid protein (N)
gene of RSV types A and B by real-time RT-PCR on a Smart-
Cycler (Cepheid, Sunnyvale, CA). After the rapid antigen as-
say was performed, the samples in viral transport media were
frozen at 70°C until the nucleic acids from the samples were
extracted, but no more than 2 months after sample collection.
The external lysis protocol of a Roche total-nucleic-acid isola-
tion kit on a MagNAPure LC (Roche Applied Science, Indi-
anapolis, IN) was used, with 200 l of each sample eluted into
50 l. The sample preparation control bead included in the
ASR was added to the lysis buffer prior to extraction, allowing
for detection of PCR inhibition. QIAGEN’s One-Step RT-
PCR kit (QIAGEN, Valencia, CA) was used for the reverse
transcriptase reaction, and Cepheid’s RSV ASR were used for
the real-time PCR. Each reaction mixture included 5 l of
extracted nucleic acid and 20 l of the following mixture: 1
QIAGEN One-Step RT-PCR buffer, 2 l of One-Step RT-
PCR enzyme mixture, 400 M of each deoxynucleoside
triphosphate, 20 units of RNase inhibitor (New England Bio-
labs, Ipswich, MA), a volume of nuclease-free water sufficient
to reach a total volume of 40 l, and one RSV ASR bead. The
ASR assay was performed on a SmartCycler, using the follow-
ing cycling parameters: reverse transcription for one cycle at
48°C for 900 s and one cycle at 95°C for 900 s and amplification
for 50 cycles at 94°C for 15 s, 60°C for 30 s, and 72°C for 15 s.
The analytical lower limit of detection for the RSV ASR was
determined to be 12 copies/reaction (586 copies/ml) by using
diluted nucleic acid extracted from purified quantified RSV
(Advanced Biotechnologies, Columbia, MD). For the preci-
sion studies, the nucleic acid was extracted daily and diluted
with nuclease-free water to 586 copies/ml. Intrarun precision
was determined by testing the lower limit of detection for five
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consecutive days, and interrun precision was determined by
assaying five replicates on two consecutive days. Statistical
analysis was performed using CLSI guidelines (4). The average
cycle threshold for intrarun variability was 0.81, with an aver-
age coefficient of variation of 2.0%, and the cycle threshold for
interrun variability was 0.85, with a coefficient of variation of
2.1%. These data indicate that results obtained using the RSV
ASR have excellent reproducibility. In addition, the ASR showed
no cross-reactivity when tested against the microorganisms listed
in Table 1.
The ASR identified 56% (n  79) of the specimens as
positive. This is a significant increase, with 22% (n  31) more
samples being RSV positive by RT-PCR. While no published
studies evaluate Cepheid’s RSV ASR, the observed increase is
consistent with the few published studies that have compared
RSV rapid antigen detection to molecular detection (12, 15,
18). Of the ASR-positive samples, 75% (n  59) were from
individuals less than 1 year of age, 19% (n  15) from indi-
viduals 1 to 5 years of age, and 6% (n  5) from individuals
greater than 5 years of age. Since it has been reported that
older individuals tend to have lower viral burdens during RSV
infection, one theory is that older patients would be more likely
to have false-negative rapid antigen tests (3, 6, 8). However,
only 13% (n  2) of patients greater than 5 years of age and
33% (n  10) of patients 1 to 5 years of age were rapid antigen
assay negative and PCR positive. For patients less than 1 year
of age, 11% (n  20) were positive by PCR only. Though the
sample size is limiting, there is not a striking association be-
tween increased age and false-negative rapid antigen assay
results. The breakdown of ASR results compared to rapid
antigen assay results is shown in Table 2. All discrepant results
were confirmed by chart review. Patients positive by PCR only
were clinically diagnosed with bronchiolitis (n  32). There was
one PCR-negative/rapid antigen assay-positive patient with no
respiratory symptoms; upon repeat of the rapid antigen assay, this
sample was negative. However, it should be noted that the sample
was frozen for 2 months prior to retesting. In our hands, the
sensitivity and specificity of the BD Directigen RSV assay were
59% and 98%, respectively, using a combination of PCR and
chart review as the gold standard.
Since the number of false negatives (23%, n  32) is sub-
stantial for the Directigen RSV rapid antigen assay, it is rec-
ommended that physicians order RSV RT-PCR on specimens
with negative rapid antigen tests for the most accurate labora-
tory diagnoses. Ideally, if an appropriate turnaround time can
be offered, molecular detection should be the gold standard
offered at all times for RSV diagnosis. While PCR is more
expensive and requires more technologist time and skill, the
increased accuracy of the results justifies the extra resources
required, particularly for inpatients. In the inpatient setting,
where the time required for the result is less critical than test
accuracy, the use of PCR for RSV detection will potentially
eliminate the need for unnecessary additional testing and an-
timicrobial therapy, benefiting both the patient and the insti-
tution. However, if the time required for the result is critical, as
in the outpatient setting, the rapid antigen assay is more ap-
propriate, providing results in about 15 min. Although the
RT-PCR assay requires as little as 4 h, many laboratories
would need to employ batch processing to maintain cost-effec-
tiveness, thus lengthening the achievable turnaround time to
beyond what is effective for the outpatient setting. However,
the ASR are contained in a lyophilized bead that decreases the
amount of skill and time required to set up the PCR while
permitting the most accurate results.
(A preliminary report of this work has been presented pre-
viously [9a].)
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TABLE 1. Microorganisms which do not show cross-reactivity in


















Bacterial spp. and strains
Streptococcus pyogenese
Streptococcus pneumoniae ATCC 49619a,d
Haemophilus influenzaee
Moraxella catarrhalise
Staphylococcus aureus ATCC 29213d,e
Legionella pneumophila ATCC 33152a,d
Mycobacterium abscessusa
Mycobacterium chelonae ATCC 35752d
Mycobacterium fortuitum ATCC 6841d




a Isolate obtained from clinical material.
b Reference material obtained from BBI Diagnostics (West Bridgewater,
MA).
c Reference material obtained from Advanced Biotechnologies (Columbia,
MD).
d Reference material obtained from ATCC (Manassas, VA).
e Multiple strains obtained from clinical specimens were tested.
TABLE 2. Sensitivity and specificity of the Directigen RSV assay,
using the Cepheid RSV ASR and chart review
as the gold standard
Result for Directigen
RSV assaya





a The sensitivity and specificity of the Directigen RSV assay were 59% and
98%, respectively.
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